CHERYL VALLIE: Open Payments
NPI 1417941410 · MIDLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$764 in 34 payments from 14 companies in 2025. Trend: 2023 $2,231 · 2024 $1,102 · 2025 $764
Food & beverage: $764
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $278 |
| ABBVIE INC. | 4 | $157 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| PFIZER INC. | 2 | $32 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
Products named: Ozempic, VRAYLAR, JARDIANCE, Saxenda, REXULTI, CAPLYTA, FASENRA, QULIPTA.
Industry payments across TX — which companies pay providers there.
